269 related articles for article (PubMed ID: 15314491)
41. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
42. Abnormalities of the type I interferon signaling pathway in lupus autoimmunity.
Gallucci S; Meka S; Gamero AM
Cytokine; 2021 Oct; 146():155633. PubMed ID: 34340046
[TBL] [Abstract][Full Text] [Related]
43. Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus.
Feng X; Chen W; Xiao L; Gu F; Huang J; Tsao BP; Sun L
Lupus; 2017 Jan; 26(1):62-72. PubMed ID: 27230555
[TBL] [Abstract][Full Text] [Related]
44. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus.
Urbonaviciute V; Voll RE
J Intern Med; 2011 Oct; 270(4):309-18. PubMed ID: 21793951
[TBL] [Abstract][Full Text] [Related]
45. Bcl-2 antagonists kill plasmacytoid dendritic cells from lupus-prone mice and dampen interferon-α production.
Zhan Y; Carrington EM; Ko HJ; Vikstrom IB; Oon S; Zhang JG; Vremec D; Brady JL; Bouillet P; Wu L; Huang DC; Wicks IP; Morand EF; Strasser A; Lew AM
Arthritis Rheumatol; 2015 Mar; 67(3):797-808. PubMed ID: 25418983
[TBL] [Abstract][Full Text] [Related]
46. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid.
Lauwerys BR; Hachulla E; Spertini F; Lazaro E; Jorgensen C; Mariette X; Haelterman E; Grouard-Vogel G; Fanget B; Dhellin O; Vandepapelière P; Houssiau FA
Arthritis Rheum; 2013 Feb; 65(2):447-56. PubMed ID: 23203821
[TBL] [Abstract][Full Text] [Related]
47. Interferon-alpha: a therapeutic target in systemic lupus erythematosus.
Crow MK
Rheum Dis Clin North Am; 2010 Feb; 36(1):173-86, x. PubMed ID: 20202598
[TBL] [Abstract][Full Text] [Related]
48. Interferon regulatory factors in human lupus pathogenesis.
Salloum R; Niewold TB
Transl Res; 2011 Jun; 157(6):326-31. PubMed ID: 21575916
[TBL] [Abstract][Full Text] [Related]
49. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process.
Papadimitraki ED; Choulaki C; Koutala E; Bertsias G; Tsatsanis C; Gergianaki I; Raptopoulou A; Kritikos HD; Mamalaki C; Sidiropoulos P; Boumpas DT
Arthritis Rheum; 2006 Nov; 54(11):3601-11. PubMed ID: 17075805
[TBL] [Abstract][Full Text] [Related]
50. Low-density granulocytes are related to shorter pregnancy duration but not to interferon alpha protein blood levels in systemic lupus erythematosus.
Torell A; Stockfelt M; Larsson G; Blennow K; Zetterberg H; Leonard D; Rönnblom L; Saleh M; Sjöwall C; Strevens H; Jönsen A; Bengtsson AA; Trysberg E; Sennström MM; Zickert A; Svenungsson E; Gunnarsson I; Christenson K; Bylund J; Jacobsson B; Rudin A; Lundell AC
Arthritis Res Ther; 2023 Jun; 25(1):107. PubMed ID: 37349744
[TBL] [Abstract][Full Text] [Related]
51. Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells.
Yan B; Ye S; Chen G; Kuang M; Shen N; Chen S
Arthritis Rheum; 2008 Mar; 58(3):801-12. PubMed ID: 18311820
[TBL] [Abstract][Full Text] [Related]
52. Characterization of 5C11-positive activated interferon-producing cells in patients with systemic lupus erythematosus.
Ohshima M; Kanda H; Kubo K; Yonezumi-Hayashi A; Tateishi S; Yamamoto K
Lupus; 2013 Jan; 22(1):44-51. PubMed ID: 23087259
[TBL] [Abstract][Full Text] [Related]
53. Type I interferon signature in systemic lupus erythematosus.
Bezalel S; Guri KM; Elbirt D; Asher I; Sthoeger ZM
Isr Med Assoc J; 2014 Apr; 16(4):246-9. PubMed ID: 24834763
[TBL] [Abstract][Full Text] [Related]
54. Pin1-Targeted Therapy for Systemic Lupus Erythematosus.
Wei S; Yoshida N; Finn G; Kozono S; Nechama M; Kyttaris VC; Zhen Zhou X; Tsokos GC; Ping Lu K
Arthritis Rheumatol; 2016 Oct; 68(10):2503-13. PubMed ID: 27159270
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of TLR9 expression on PBMCs and CpG ODN-TLR9 ligation on IFN-α production in SLE patients.
Mortezagholi S; Babaloo Z; Rahimzadeh P; Namdari H; Ghaedi M; Gharibdoost F; Mirzaei R; Bidad K; Salehi E
Immunopharmacol Immunotoxicol; 2017 Feb; 39(1):11-18. PubMed ID: 28049380
[TBL] [Abstract][Full Text] [Related]
56. High
Wang T; Marken J; Chen J; Tran VB; Li QZ; Li M; Cerosaletti K; Elkon KB; Zeng X; Giltiay NV
Front Immunol; 2019; 10():1243. PubMed ID: 31231380
[TBL] [Abstract][Full Text] [Related]
57. Contribution of dendritic cells to the autoimmune pathology of systemic lupus erythematosus.
Mackern-Oberti JP; Llanos C; Riedel CA; Bueno SM; Kalergis AM
Immunology; 2015 Dec; 146(4):497-507. PubMed ID: 26173489
[TBL] [Abstract][Full Text] [Related]
58. Association between anti-interferon-alpha autoantibodies and COVID-19 in systemic lupus erythematosus.
Gupta S; Nakabo S; Chu J; Hasni S; Kaplan MJ
medRxiv; 2020 Nov; ():. PubMed ID: 33184616
[TBL] [Abstract][Full Text] [Related]
59. Autoantibodies against IFNα in patients with systemic lupus erythematosus and susceptibility for infection: a retrospective case-control study.
Beydon M; Nicaise-Roland P; Mageau A; Farkh C; Daugas E; Descamps V; Dieude P; Dossier A; Goulenok T; Farhi F; Mutuon P; Timsit JF; Papo T; Sacre K
Sci Rep; 2022 Jul; 12(1):11244. PubMed ID: 35788140
[TBL] [Abstract][Full Text] [Related]
60. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus.
Bayry J; Lacroix-Desmazes S; Delignat S; Mouthon L; Weill B; Kazatchkine MD; Kaveri SV
Arthritis Rheum; 2003 Dec; 48(12):3497-502. PubMed ID: 14674000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
